Immunic, Inc. (IMUX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immunic, Inc. (IMUX) closed at USD 6.66 on 2026-10-14, a change of -20.7 % over the past year, with a market capitalization of USD 96.88M.

Immunic, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immunic, Inc. key figures

Previous close

USD 6.66 (2026-10-14)

1-year change

-20.7 %

Market cap

USD 96.88M

Enterprise value

USD -57.66M

P/E ratio (trailing)

-1.92

P/E ratio (forward)

-2.93

EPS (trailing)

-3.69

EPS (forward)

-2.43

PEG ratio

n/a

Price to book

0.76

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.16

Employees

100

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immunic, Inc.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immunic, Inc. and compare it with other stocks.